Kiniksa Pharmaceuticals Q3 2024 GAAP EPS $(0.18) May Not Be Comparable To $0.04 Estimate, Sales $112.21M Beat $111.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kiniksa Pharmaceuticals reported a Q3 2024 GAAP EPS of $(0.18), missing the $0.04 estimate, but sales of $112.21M beat the $111.52M estimate. Sales increased by 67.37% compared to the same period last year.
October 29, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kiniksa Pharmaceuticals reported a Q3 2024 GAAP EPS of $(0.18), significantly missing the $0.04 estimate. However, sales of $112.21M slightly beat the $111.52M estimate, showing a strong 67.37% year-over-year increase.
The significant miss on EPS compared to estimates is likely to negatively impact the stock price in the short term, despite the positive sales performance. The market often reacts more strongly to earnings misses than sales beats.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100